Company intelligence / Profile preview

Phyrago

Ann Arbor, Michigan, United Statesphyrago.com ↗

Ownership: Private
Development stage: Other

Overview

Phyrago is a preclinical-stage biotechnology company dedicated to developing novel therapeutics for the treatment of inflammatory and fibrotic diseases. Spun out from the University of Michigan, the company focuses on targeting Galectin-3, a protein that plays a critical role in the progression of fibrosis and chronic inflammation. Their lead programs are aimed at addressing high unmet needs in conditions such as systemic sclerosis (scleroderma) and rheumatoid arthritis. By inhibiting Galectin-3, Phyrago aims to halt or reverse tissue scarring and improve patient outcomes in debilitating autoimmune disorders.

Therapeutic areas: ImmunologyRheumatologyOther
Modalities: Small molecule
Industry: Biotech

Partnerships

University of Michigan

Beyond the preview

Go deeper on Phyrago.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phyrago.

Explore the full profile